Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint ...Middle East

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi,...

Hence then, the article about jacobio pharma announced its kras g12c inhibitor reached the primary endpoint was published today ( Wednesday 01/05/2024 - 04:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint )

Also on site :

• ‘Motor City’ Review: Potsy Ponciroli’s Audacious Thriller — a Scorsese Opera without Dialogue — Announces the Arrival of a Startling Voice
• Skating Legend, Who Entered the 1988 Winter Olympics as an Underdog, Delivered One of Figure Skating's Greatest Routines
• Complain Campaign: Michelle Obama Is Angry the Media Treated Her As a Fashion Icon, Not a Great Orator